Glycoconjugates
- Name
- Glycoconjugates
- Accession Number
- DBCAT000084
- Description
Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed)
- Drugs
Drug Drug Description Pegfilgrastim A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. Filgrastim A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Oritavancin An antibacterial agent used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria. Human C1-esterase inhibitor A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema. Protein C A medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis. Bleomycin A chemotherapy agent used to treat various malignancies, including head and neck malignancy, lymphoma, and testicular tumors, among others. Vancomycin A glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA (methicillin-resistant Staphylococcus aureus) infections. TU-514 Not Available Phosphoramidon Not Available Balhimycin Balhimycin is a novel glycopeptide antibiotic. Sulfatide Any of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers and may accumulate in metachromatic leukodystrophy. LJP 1082 Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis. Cefilavancin Investigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections. Teicoplanin A glycopeptide antibiotic with a similar mechanism of action and spectrum of activity to vancomycin used to treat various infections caused by gram-positive bacteria. Dalbavancin An antibacterial used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria. Telavancin An antibacterial agent used in the treatment of complicated skin and skin structure infections and types of hospital-acquired bacterial pneumonia. Ulinastatin Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug. KRN-7000 KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients... Siagoside Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a... Rivipansel Rivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others. Bleomycin A6 Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug... Ceramide NP Ceramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3... Ceramide AP Not Annotated Ceramide NG Not Annotated Uproleselan Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML). Imgatuzumab Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With... Naxitamab A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. ABX-196 ABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma). Simoctocog alfa An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Darbepoetin alfa A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Erythropoietin A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Sargramostim A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. Drotrecogin alfa A form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII. Alpha-1-proteinase inhibitor A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency. Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Thyroglobulin For the treatment of hypothyroidism (deficiency in the production of thyroid hormone). Adecatumumab Investigated for use/treatment in breast cancer and prostate cancer. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Regramostim Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant. Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. Thrombomodulin Alfa Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. Pegdinetanib Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration. Thrombopoietin Investigated for use/treatment in thrombocytopenia. TG4010 Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer. Methoxy polyethylene glycol-epoetin beta A synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease. Conestat alfa A recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. Gastric intrinsic factor Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic... Epoetin delta Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo. Muplestim Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in... Molgramostim Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis. Tecemotide Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung. Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Lenograstim A granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors. Protein S human A medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy. Lipegfilgrastim A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. Sulglicotide Not Annotated Zinpentraxin alfa Zinpentraxin alfa is a recombinant form of PTX-2, a naturally circulating human protein. It is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With... Eflapegrastim A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Recombinant CD40-ligand Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma). Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Fibronectin Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix). Avidin Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach). Lactoferrin Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis). Tengonermin Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.... GI-6207 Not Annotated EDI-200 EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1. Hemopexin Not Annotated - Drugs & Drug Targets